First-pass extracted concept

LivGETx-CVD

Candidate: concept label1 source documents3 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

The review highlights ongoing clinical trials employing liver-targeted in vivo editing modalities (LivGETx-CVD).

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1challenge summarysupports2026Source 1DOI PubMed

The review identifies delivery, off-target effects, genotoxicity, and immunogenicity as challenges for gene editing therapies targeting lipid metabolism in cardiovascular disease.

Quoted textsource-backed

and provides insights into challenges in delivery, off-target effects, genotoxicity, and immunogenicity.

Claim 2clinical progress summarysupports2026Source 1DOI PubMed

The review highlights ongoing clinical trials employing liver-targeted in vivo editing modalities referred to as LivGETx-CVD.

Quoted textsource-backed

The review highlights ongoing clinical trials employing liver-targeted in vivo editing modalities (LivGETx-CVD)

Claim 3therapeutic positioningsupports2026Source 1DOI PubMed

The review positions gene editing as a potentially transformative single-dose strategy for prevention and long-term management of dyslipidemia and atherosclerotic cardiovascular disease.

Quoted textsource-backed

Collectively, this review captures the rapid progress of LivGETx-CVD from conceptual innovation to clinical application, and positions gene editing as a transformative, single-dose strategy with the potential to redefine prevention and long-term management of dyslipidemia and atherosclerotic cardiovascular disease.